<DOC>
	<DOCNO>NCT00824135</DOCNO>
	<brief_summary>Patients refractory hematologic malignancy include develop recurrent disease allogeneic hematopoietic stem cell transplantation ( HSCT ) dismal prognosis . Historically , regimen-related mortality disease recurrence significant cause treatment failure heavily pre-treated patient population . The investigator institution utilized mismatch family member donor patient several reason : ( 1 ) Only 30 % patient match related donor available ; ( 2 ) transplantation perform rapidly since time unrelated donor trans-plantation average 3 4 month ; ( 3 ) alloimmune reactivity natural killer ( NK ) cell follow haploidentical HSCT show reduce relapse rate certain patient group ; , ( 4 ) curative treatment option available . In present trial , investigator propose novel condition regimen use clofarabine effort enhance cytotoxicity simultaneously reduce regimen related toxicity . In phase I trial , goal determine maximum tolerate dose ( MTD ) clofarabine use combination melphalan thiotepa pre-transplant .</brief_summary>
	<brief_title>Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies</brief_title>
	<detailed_description>The primary objective trial determine maximum tolerate dose clofarabine combination thiotepa melphalan condition regimen haploidentical stem cell transplant engineer graft deplete CD3+ cell . Study participant child young adult refractory hematologic malignancy . Secondary objective include follow : - To describe one-year overall survival ( OS ) event-free survival ( EFS ) rate study participant . - To determine time hematopoietic recovery donor cell engraftment follow study treatment . - To estimate cumulative incidence relapse study participant . - To estimate incidence overall grade II-IV grade III-IV acute GVHD rate chronic GVHD . - To estimate incidence describe cause non-hematologic regimen-related toxicity regimen-related mortality first 100 day post HSCT . - To explore biologic significance soluble interleukin-2 ( IL-2 ) receptor , tumor necrosis factor ( TNF ) , lymphocyte reconstitution ( qualitative quantitative , V beta spectratyping , TREC</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Age le equal 21 year old ; may great 21 year old previously treat St. Jude patient within 3 year completion recent prior disease specific therapy . One follow refractory hematologic malignancy ( chemoresistant relapse primary induction failure ) diagnose : ALL AML ( &gt; 25 % blast bone marrow ) secondary AML/MDS CML accelerate phase blast crisis juvenile myelomonocytic leukemia ( JMML ) myelodysplastic syndrome ( MDS ) Hodgkin nonHodgkin lymphoma ( NHL ) residual recurrent disease follow autologous HSCT , unable undergo autologous HSCT due chemoresistant disease inability acceptable quantity tumorfree stem cell collect ( &gt; 1 x 108 TNC/kg marrow &gt; 1 x 106 CD34+/kg PBS patient hematologic malignancy undergone prior allogeneic HSCT comorbid condition medical opinion medical faculty ( Division Bone Marrow Transplantation Cellular Therapy ) make standard myeloablation prohibitive Does active malignancy one transplant indicate Cardiac shorten fraction great equal 25 % For pediatric patient , creatinine clearance great equal 90 ml/min/1.73 m2 accord Schwartz formula estimate GFR ( ml/min/1.73m2 ) = k*height ( cm ) /serum creatinine ( mg/dL ) . k proportionality constant varies age function urinary creatinine clearance per unit body size ; 0.45 12 month age ; 0.55 child adolescent girl ; 0.70 adolescent boy For adolescent adult patient , serum creatinine 1.0 mg/dL ; serum creatinine 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must 60 mL/min/1.73 m2 calculate Modification Diet Renal Disease equation predict GFR ( ml/min/1.73 m2 ) = 186 x ( serum creatinine ) 1.154 x ( age year ) 0.023 x ( 0.742 patient female ) x ( 1.212 patient black ) Forced vital capacity ( FVC ) great equal 40 % predict value pulse oximetry great equal 92 % room air . Karnofsky Lansky ( agedependent ) performance score great equal 50 ( See APPENDIX A ) Does active acute active chronic GVHD define require medical therapy . Does active acute bronchiolitis obliterans ( BO ) bronchiolitis obliterans organize pneumonia ( BOOP ) . Has suitable HLA partially match family member donor available stem cell donation Bilirubin le equal 1.5 time upper limit normal age . Alanine aminotransferase ( ALT ) less equal 1.5 time upper limit normal age . Aspartate aminotransferase ( AST ) less equal 1.5 time upper limit normal age . Not pregnant ( confirmed negative serum urine pregnancy test within 14 day prior enrollment ) . Not lactate Inclusion criterion ( stem cell donor ) : Partially HLAmatched family member . At least 18 year age . HIV negative Not pregnant ( confirmed negative serum urine pregnancy test within 14 day prior enrollment ) . Not lactate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Stem Cell Transplantation , Hematopoietic</keyword>
	<keyword>Peripheral Blood Stem Cell Transplantation</keyword>
	<keyword>Maximal Tolerated Dose</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Hematological Malignancies</keyword>
	<keyword>Apheresis</keyword>
</DOC>